Approximately 70% of TCs have BRAF gene point mutations, and BRAFV600E mutations in PTC patients are associated with invasive tumour phenotypes and increased risk of tumour recurrence, as the early mutations of the driving gene BRAF can alter the epigenetics of thyroid tumour tissue [27]. Here, BRAF is linked to thyroid tumor.